BCR and cancer: In our exploratory data analysis experience of studying precision-oncology drugs for the treatment of metastatic colorectal cancer patients (diagnosed between 2006 and 2013), problems arose because the BCR does not provide any long-term follow-up (i.e., tumor response) or biomarker information (i.e., molecular targets associated with the cancer).